胸部椎体放疗剂量与肺癌同步放化疗急性血液学毒性相关:单中心回顾性分析
该单中心回顾性分析纳入2007至2016年接受根治性同步铂类双药化疗的201例肺癌患者,评估胸部椎体放疗剂量与≥3级血液学毒性的关联。结果显示,胸部椎体平均剂量及低剂量参数V5-V20与≥3级血液学毒性独立相关,LKB模型提示骨髓行为类似并行器官, spared dose可能降低严重血液学毒性。
要点
- 胸部椎体V5至V20升高与≥3级血液学毒性风险增加相关,多因素分析中持续存在。
- LKB模型参数n=1提示骨髓为并行器官,平均剂量是有效预测因子。
核心结论
- 胸部椎体平均剂量和低剂量参数(V5-V20)与肺癌同步放化疗≥3级血液学毒性相关。
- LKB模型显示骨髓行为类似并行器官(n=1),平均胸部椎体剂量是有用的毒性预测因子。
- 数据提示减少胸部椎体照射剂量可能降低严重血液学毒性发生率。
研究设计与样本
- 单中心回顾性分析,纳入2007至2016年接受根治性同步铂类双药化疗的NSCLC和SCLC患者201例。
- 多数为NSCLC(n=162,81%)和III至IV期疾病(n=179,89%)。
- 全部患者接受顺铂/依托泊苷(n=107,53%)或卡铂/紫杉醇(n=94,47%)。
- 中位放疗剂量60 Gy(范围60-70 Gy)。
- 回顾记录胸部椎体平均剂量和V5-V60,采用逻辑回归分析≥3级血液学毒性与剂量学/临床参数的关联。
主要发现
- ≥3级血液学毒性发生率为49%(n=99)。
- 胸部椎体V5至V20升高同样与≥3级血液学毒性风险升高相关,多因素分析中持续存在。
- 高于最佳切点(V5=65%、V10=60%、V20=50%、平均剂量=23.5 Gy)的患者≥3级血液学毒性风险约增加2倍。
关键数值与推荐
- LKB模型约束优化得到≥3级血液学毒性参数:n=1,m=1.79,TD50=21.4 Gy。
- ROC分析确定最佳切点:V5=65%、V10=60%、V20=50%、平均剂量=23.5 Gy。
- 高于上述切点的患者≥3级血液学毒性风险约增加2倍。
临床怎么用
- 在肺癌同步放化疗计划评估中,可关注胸部椎体平均剂量及V5-V20等低剂量参数。
- 可参考V5=65%、V10=60%、V20=50%、平均剂量=23.5 Gy作为胸部椎体剂量约束的候选切点。
- 努力减少胸部椎体照射剂量可能有助于降低严重血液学毒性发生率。
局限性
- 单中心回顾性分析,结果需外部验证。
- 样本以NSCLC和III至IV期患者为主,其他人群适用性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To test the hypothesis that increasing radiation therapy (RT) dose to the thoracic vertebral bodies (TVBs) contributes to the development of hematologic toxicities (HTs) in patients with lung cancer. METHODS AND MATERIALS: Cases of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) treated with definitive chemoradiation with concurrent platinum-based doublet chemotherapy at our institution from 2007 to 2016 were identified. Mean TVB dose and the volume of TVBs receiving at least 5 to 60 Gy (V5-V60) were retrospectively recorded. Logistic regression was used to test associations between grade ≥3 HT (HT3+) and dosimetric/clinical parameters. Normal tissue complication probability was evaluated using the Lyman-Kutcher-Burman (LKB) model for HT3+, and receiver operating characteristics analysis was used to determine dosimetric cut-points. RESULTS: We identified 201 patients, the majority having NSCLC (n=162, 81%) and stage III to IV disease (n=179, 89%). All patients received either cisplatin/etoposide (n=107, 53%) or carboplatin/paclitaxel (n=94, 47%). Median RT dose was 60 Gy (range, 60-70 Gy). The rate of HT3+ was 49% (n=99). Increasing mean TVB dose (per Gy) was associated with higher odds of developing HT3+ (odds ratio 1.041, 95% confidence interval 1.004-1.080, P=.032), as were increasing TVB V5 to V20. These dosimetric correlates to HT3+ persisted on multivariate analysis. Constrained optimization of the LKB model for HT3+ yielded the parameters: n=1, m=1.79, and TD50=21.4 Gy. Optimal cut-points identified were V5=65%, V10=60%, V20=50%, and mean dose=23.5 Gy. Patients with values above these cut-points had an approximately 2-fold increased risk of HT3+. CONCLUSIONS: We found that mean TVB dose and low-dose parameters (V5-V20) were associated with HT3+ in chemoradiation for lung cancer. Per the LKB model, bone marrow behaves like a parallel organ (n=1), implying that mean TVB dose is a useful predictor for toxicity. These data suggest that efforts to spare dose to the TVBs may reduce rates of severe HT.
引用
- Barney CL, Scoville N, Allan E, et al. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 29413286. doi:10.1016/j.ijrobp.2017.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。